

Uncovering Mechanisms from Immune-Based Therapy in Cancer and Autoimmunity (B3)

February 18-22, 2019 • Beaver Run Resort • Breckenridge, Colorado, USA

Scientific Organizers: Daniel J. Cua, E. John Wherry and Carla V. Rothlin

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Organized in collaboration with Cancer Research UK

Supported by the Directors' Fund

Abstract & Scholarship Deadline: October 17, 2018 / Abstract Deadline: November 15, 2018 / Discounted Registration Deadline: December 18, 2018

MONDAY, FEBRUARY 18

Arrival and Registration

TUESDAY, FEBRUARY 19

Welcome and Keynote Address

Arlene H. Sharpe, Harvard Medical School, USA
Checkpoint Blockade for Cancer Immunotherapy

Checkpoint Blockade Predisposes Patients to Autoimmunity

Jeffrey A. Bluestone, University of California, San Francisco, USA
Autoimmune AE in Cancer Immunotherapy

Jennifer Ann Wargo, University of Texas MD Anderson Cancer Center, USA
Immune Mechanisms Influencing Checkpoint Therapy

Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA
Regulation of Autoimmunity and Cancer by PD-1 and LAG3

Short Talk(s) Chosen from Abstracts

Genetics of Autoimmunity and Cancer: What are the Common Denominators?

Alex Marson, University of California, San Francisco, USA
Decoding T Cell Circuitry

Stuart G. Tangye, Garvan Institute of Medical Research, Australia
Common Genetic Hits in Cancer and Autoimmunity

Wenjun Ouyang, Amgen, Inc., USA
Lessons from Human Genetics for Autoimmunity and Cancer Therapy

Short Talk Chosen from Abstracts

Poster Session 1

WEDNESDAY, FEBRUARY 20

Cellular Reprogramming: Regulatory vs. Functional Fate

Alexander Y. Rudensky, HHMI/Memorial Sloan Kettering Cancer Center, USA
Treg Stability in Disease

Mark S. Anderson, University of California, San Francisco, USA
Modulating Self-Tolerance in Autoimmunity and Cancer

Maria Grazia Roncarolo, Stanford University School of Medicine, USA
T Regulatory Cell-Based Therapy in Cancer and Autoimmunity

Speaker to be Announced
Lessons from "Case Studies" of Cancer Immunotherapy Promoting Autoimmunity

Short Talk(s) Chosen from Abstracts

Workshop 1: Immune Monitoring of Checkpoint Blockade Therapies

Short Talks Chosen from Abstracts

Cellular Reprogramming: CD8 T Cell Exhaustion and CD4 T Cell Lineages

E. John Wherry, University of Pennsylvania, USA
T Cell Exhaustion and Fate Decisions – Implications for Immunotherapy

Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Epigenetics of Tumor Immunity

W. Nicholas Haining, Dana-Farber Cancer Institute, USA
Epigenetic Engineering of Tumor Immunity

Short Talk Chosen from Abstracts

Poster Session 2

THURSDAY, FEBRUARY 21

Macrophage Biology, Tissue Repair, Autoimmunity and Cancer

Mikael J. Pittet, Massachusetts General Hospital, USA
Myeloid Cells in Cancer Therapies

Carla V. Rothlin, Yale University, USA
Coincidence Detectors in Tissue Repair

Ming O. Li, Memorial Sloan Kettering Cancer Center, USA
Differentiation and Function of Tumor-associated Macrophages

Fiona M. Powrie, University of Oxford, UK
Inflammation Driven Cancer: Host and Microbial Pathways

Short Talk(s) Chosen from Abstracts

Neutrophils and MDSCs in Host Defense and Cancer

Matthew F. Krummel, University of California, San Francisco, USA
Myeloid Cells as Arbiters of Self

Catherine Hedrick, La Jolla Institute for Allergy and Immunology, USA
Talk Title to be Announced

Susan M. Kaech, The Salk Institute, USA
Talk Title to be Announced

Dmitry I. Gabrilovich, Wistar Institute, USA
MDSCs in Cancer

Short Talk Chosen from Abstracts

Poster Session 3

FRIDAY, FEBRUARY 22

Finding the Cure for Cancer

Drew M. Pardoll, Johns Hopkins University School of Medicine, USA
Checkpoint Inhibition

Alan J. Korman, Bristol-Myers Squibb, USA
Immune Checkpoint Blockade and Adverse Events in Mice, Cynos and Man

Emmett V. Schmidt, Merck Research Labs, USA
Drivers in the Clinical Development of Cancer Combination Therapy – Pembrolizumab Combination Therapies, Emerging Results

Speaker to be Announced

Short Talk(s) Chosen from Abstracts

Integrated Themes across Preclinical and Clinical Treatment of Cancer and Autoimmunity

Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
What we can Learn from Combination Immunotherapy

KEYSTONE SYMPOSIA
on Molecular and Cellular Biology

Uncovering Mechanisms from Immune-Based Therapy in Cancer and Autoimmunity (B3)

February 18-22, 2019 • Beaver Run Resort • Breckenridge, Colorado, USA

Scientific Organizers: Daniel J. Cua, E. John Wherry and Carla V. Rothlin

Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Organized in collaboration with Cancer Research UK

Supported by the Directors' Fund

Abstract & Scholarship Deadline: October 17, 2018 / Abstract Deadline: November 15, 2018 / Discounted Registration Deadline: December 18, 2018

Hergen Spits, University of Amsterdam, Netherlands
*Harnessing the Power of the Immune System for Therapy: Past
Present and Future*

Daniel J. Cua, Merck Research Laboratories, USA
Autoimmunity

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

SATURDAY, FEBRUARY 23

Departure